Abstract 7411: Proteotranscriptomic dissection of breast cancer T cell states identifies CD103+ Tfh-derived cytotoxic CD4+ cells linked to immunotherapy response

Le résumé fourni par la source

Abstract While cancer immunotherapies have primarily focused on activation of cytotoxic CD8 killing, CD4 T cell activity is also associated with survival and immunotherapeutic response in numerous cancers. We applied integrated single-cell RNA sequencing and multiplexed protein epitope profiling to breast cancer samples to resolve the complexity of immune cell states within the tumor microenvironment. This approach enhanced phenotypic resolution, identifying three distinct states within the T follicular helper (Tfh) cell cluster. A CXCR4high progenitor state gave rise to two differentiated states: an IGFL2high subset resembling conventional Tfh cells and localised to B cell-rich lymphoid aggregates, and a CD103+ subset, exhibiting features of tissue residency, exhaustion, and cytotoxicity, which co-localised with tumor foci. CD103+ Tfh-like cells were found to interact with CXCL10+ macrophages through production of CCL chemokines and CSF1. A higher CD103+ Tfh to IGFL2high Tfh ratio correlated with improved patient survival and enhanced responses to anti-PD1 checkpoint blockade. These findings integrate Tfh and CD4 with cytotoxic potential in breast cancer, offering new insight into anti-tumor immunity and response to checkpoint blockade. Citation Format: Ghamdan Al-Eryani, Sophie van der Leij, Etienne Masle-Farquhar, Alma Andersson, Kate Harvey, Sunny Wu, Tony Wang, John Reeves, Cindy Ma, Daniel L. Roden, Charles M. Perou, Nir Hacohen, Aziz Al’Khafaji, Mats Nilsson, Joakim Lundeberg, Marcel Batten, Simon Junankar, Alexander Swarbrick. Proteotranscriptomic dissection of breast cancer T cell states identifies CD103+ Tfh-derived cytotoxic CD4+ cells linked to immunotherapy response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7411.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.